Abstract
The Metabolic Syndrome is a cluster of conditions that happens together. These conditions disrupt the body glycose levels homeostasis, which leads to a resistance to respond to insulin. The thiazolidinediones (TZDs) are the main drug for the treatment of Metabolic Syndrome. It targets the ligate-dependent nuclear receptor (RN) PPAR³ where it acts as a strong agonist. The PPAR³ is a key pl…